Skip to content

KnobbeMedical.com

Johnson & Johnson to Acquire Shockwave Medical in $13.1B Deal

April 19, 2024  | Raina Patel

Johnson & Johnson (J&J) reported on April 5, 2024, that it has entered an agreement to acquire Shockwave Medical, a company in the cardiovascular medical device sector, in a deal totaling a reported $13.1 billion. The deal would further expand J&J into the cardiovascular treatment market.

Shockwave Medical has developed intravascular lithotripsy (IVL) technology, designed to address calcified plaque in blood vessels. The catheter-based treatment utilizes sonic pressure waves to disrupt calcified lesions, reportedly potentially restoring blood flow, reducing procedure times, and improving patient outcomes. By integrating Shockwave Medical’s technology into its portfolio, Johnson & Johnson stated that it aims to enhance its offerings in cardiovascular care and strengthen its position in this market segment.

Image of Shockwave Medical’s IVL System Comprising an IVL Generator and Catheter

Tim Schmid, Executive Vice President and Worldwide Chairman of J&J MedTech, stated in a press release, “Shockwave offers a truly differentiated opportunity to further enhance our leadership position in medtech, expand into additional high-growth segments, and ultimately transform the future of cardiovascular treatment.”

Cardiovascular disease reportedly remains a significant global health concern with a growing demand for advanced treatment options. By incorporating Shockwave Medical’s IVL technology, J&J reports that it seeks to address this need and provide healthcare professionals with additional tools for managing complex cardiovascular conditions. “As part of a larger, more diverse organization, with broad expertise and a core focus on improving patient outcomes, we are confident we will be able to further solidify IVL as the global standard of care for patients,” says Doug Godshall, President and CEO of Shockwave.

The deal marks J&J’s second major medtech acquisition in the past roughly 15 months after acquiring heart device maker Abiomed in December 2022 in a deal worth $16.6 billion. In November 2023, J&J also acquired Laminar, another cardiac-focused medtech company, for an initial payment of $400 million.

Follow KnobbeMedical for further updates and other news and resources for startup medical device companies.

Tags

, , , , , ,

Johnson & Johnson to Acquire Shockwave Medical in $13.1B Deal Headshot

Raina Patel

Raina Patel is in the New York office and focuses primarily on patent prosecution and patent analysis. While most of her work is in the medical device space, she also has experience in the food/beverage, fashion, and consumer products industries. While in law school, Raina helped develop patent strategies for a wide variety of inventions while working at Boston University’s Office of Technology Development. She also worked with a biotech startup organizing and advancing their patent portfolio.

New York Bar Admission Pending

View all posts published by Raina Patel
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal